Potential Drug for Canine Blood Disorder IMHA
Immune-mediated hemolytic anemia (IMHA) is a common type of anemia in dogs. This deadly blood disorder occurs when the dog’s immune system is triggered to attack its own red blood cells. Despite aggressive conventional treatments, IMHA has a very high mortality rate. Most dogs die shortly after diagnosis because therapies may take days or weeks to take effect. Thus, earlier effective treatment is critical.
To address this problem, scientists from Colorado State University investigated a promising new treatment, liposomal clodronate, which blocks red blood cell destruction. Although their data suggesting increased survival time are encouraging, the findings are not statistically significant, necessitating a larger clinical trial. An important finding of this study, however, was that no adverse effects were noted in association with the administration of liposomal clodronate or placebo liposomes in any patient.
This research was conducted by Dr. Katharine Lunn at Colorado State University.
Posted by MAFon August 11, 2012. Permalink